drugset / Trial / NCT00310531

3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women

NCT00310531

Phase 3 Completed 500 enrolled Bayer
RandomizedParallel-groupDouble-blindPrevention

Summary

The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of osteoporosis.

Timeline

Start
2004-02
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 0.014 mg Other
Comparator Raloxifene Other / unclassified 60 mg Oral

Indications

No indication recorded.